Regeneration-inducing drugs: redasemtide vs cell therapy

A regeneration-inducing drug calls the body's own stem cells instead of delivering cells

Most regenerative medicine makes the cells the product. A regeneration-inducing drug turns that around.

The usual route is to collect cells from the patient or a donor, expand them outside the body, process them if needed, and return them. Because the cells are alive, autologous or allogeneic (in Japanese) makes no difference to what follows: aseptic closed-system manufacturing, cold transport and a limited shelf life.

The new class reverses the premise. The stem cells needed for repair are already in the patient's body, especially in bone marrow. So the drug supplies a signal that calls them to the damaged site. The cells that repair the tissue are the patient's own, called out of the marrow, and the drug only pulls the trigger. The lead role belongs to those stem cells, not to the administered drug. The drug does not carry cells. It sends the signal for them to gather.

The product carries a signal for cells to gather instead of the cells themselves, and that shift changes what you inspect, from manufacturing through evaluation.

Redasemtide is a synthetic peptide taken from HMGB1

The key is a protein called HMGB1. Cells release it when they are damaged, and it works as a signal in tissue repair. It also contains a region that triggers strong inflammation, which makes the whole protein unsuitable as a drug.

Stemrim therefore took out only the active domain, the stretch that carries the stem cell regeneration activity, and made it by chemical synthesis. The result is redasemtide, with the development code S-005151, licensed out to Shionogi.

Given intravenously, it is said to mobilize mesenchymal stem cells (MSCs) from bone marrow into the blood and bring them to the injury. MSCs can differentiate into various tissues and help repair them. The recruited MSCs combine several abilities: migration, immune regulation, secretion of trophic factors and control of fibrosis. Because they do several jobs, one drug could in principle serve a wide range of diseases. That is the idea behind the design. For the other approach, culturing MSCs outside the body and transplanting them, see manufacturing mesenchymal stem cells.

Treat "one drug for many diseases" as the design's premise, not a result, until trials show it disease by disease.

What changes for manufacturing, logistics and evaluation compared with cell therapy?

The product is a synthetic peptide, not a cell. That is what matters most in daily work.

In transplant-type cell therapy, cells are cultured outside the body and put in. The product is living cells, so you need aseptic culture, cold transport and a short shelf life, and quality is judged by cell viability, phenotype and potency. In mobilization-type regeneration-inducing drugs, the patient's own stem cells are called in, the product is a synthetic peptide, handling is like that of an ordinary drug, and quality is judged by peptide purity and impurities.

Japan's PMD Act draws the line too. Products made by processing human cells are regenerative medical products (再生医療等製品), and a chemically synthesized peptide is a drug. The designation redasemtide received is an orphan drug designation. Manufacturing and quality control run under the synthetic peptide framework. Peptide solid-phase synthesis (in Japanese) and peptide impurity profiling (in Japanese) take the place that aseptic culture and viability checks hold in cell therapy. For anyone responsible for bioprocess or logistics, that difference is not small.

Not making cells does not remove the difficulty of showing that the drug works. The number and quality of stem cells mobilized are thought to vary with the patient's condition. The open problem is how to measure regeneration that happens inside the body. It resembles the question behind cell therapy potency (in Japanese), except that the indicator has to sit on the side of the body that received the drug.

Cell therapy's manufacturing and logistics burdens shrink, but the difficulty of proving the effect stays in a different form.

Domestic success, global miss: where the stroke trials stand

The stroke trials of redasemtide split between 2021 and 2026.

In December 2021, Shionogi announced that the domestic phase 2 trial met its primary endpoint. Patients were 4.5 to 24 hours from onset and not eligible for clot-dissolving treatment or for treatment that reopens the blocked vessel (recanalization therapy). In April 2023, after consulting regulators, the company revised its plan in part and said it would run a global late phase 2 trial. That trial enrolls adults with acute ischemic stroke within 25 hours of onset, compares two dose groups with placebo, and is double-blind. The trial registry lists 627 participants. It includes two populations: patients ineligible for clot-dissolving or vessel-reopening treatment, and patients eligible for it.

The result came as a topline announcement on September 9, 2026. The primary endpoint was the modified Rankin Scale (mRS) at 90 days, which scores disability from 0 (no symptoms) to 6 (death). It showed no statistically significant difference from placebo. No safety concern was found for redasemtide, and tolerability was reported as good (Shionogi's announcement). The domestic and global trials differ in the time from onset and in whether patients eligible for recanalization therapy were included, so you cannot set the two results side by side without care. A detailed analysis awaits later announcements.

Redasemtide also has a second indication. For dystrophic epidermolysis bullosa (栄養障害型表皮水疱症), a rare inherited disease that makes the skin extremely fragile, it received an orphan drug designation in Japan in 2023. The same-day announcement reported that an additional phase 2 study met its primary endpoint, closure of refractory ulcers, in 3 of 4 cases. In some cases other signs, such as the area of ulcers across the body, also improved. But the study was single-arm and open-label, with only 4 cases, so it carries less weight than the stroke trial.

Read case count, blinding and patient population separately, because a small trial's result need not repeat in the next one.

Questions to ask when you read about a regeneration-inducing drug

Use these when an article or announcement crosses your desk.

1. What is the product's substance: a cell or a drug (a peptide)? Do the constraints of cell therapy apply as they are?
2. What trial supports "it works"? How many patients, was it blinded, and was it compared with placebo?
3. Are the trial's patients narrowed by time from onset or by prior treatment? Is the next trial's population the same?
4. Is the explanation of the mobilization mechanism based on animal or test-tube results, or confirmed in patients?
5. At what point in development was the announcement made, and for which indication? Has it been updated by the latest announcement from Shionogi and Stemrim?

To learn about manufacturing and quality, start with the article on recombinant versus synthetic routes for peptides (in Japanese). For the cell side, compare products in the MSC culture media directory.